H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Beyondspring Inc (BYSI) today and set a price target of $60. The company’s shares opened today at $24.49.
Pantginis wrote:
“Valuation and risks to price target achievement. We reiterate our Buy rating and $60 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s lead asset, Plinabulin. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -17.7% and a 27.4% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Strata Skin Sciences Inc.
Currently, the analyst consensus on Beyondspring Inc is a Moderate Buy with an average price target of $47.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $34 and a one-year low of $16.15. Currently, Beyondspring Inc has an average volume of 6,995.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BeyondSpring, Inc. is a clinical stage company, which engages in the development of cancer therapies. It focuses on non-small cell lung cancer, neutropenia prevention, and plinabulin and nivolumab. The company was founded by Lan Huang and Lin Qing Jia in 2013 and is headquartered in New York, NY.
